Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of galectin-3-targeted therapeutics for patients with MASH cirrhosis and portal hypertension, today announced that the U.S. Food and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback